Compare ALLT & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | EBS |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 312.8M |
| IPO Year | 2006 | 2006 |
| Metric | ALLT | EBS |
|---|---|---|
| Price | $7.97 | $6.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $12.40 | $12.00 |
| AVG Volume (30 Days) | 242.4K | ★ 1.1M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | $15.84 | $1.29 |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.12 | $4.36 |
| 52 Week High | $11.92 | $14.06 |
| Indicator | ALLT | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 56.06 |
| Support Level | $7.38 | $4.36 |
| Resistance Level | $8.12 | $6.60 |
| Average True Range (ATR) | 0.25 | 0.34 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 59.82 | 78.18 |
Allot Ltd is a provider of security and network intelligence solutions for mobile, fixed, and cloud service providers, as well as enterprises. It offers network-based security solutions such as mobile security, DDoS protection, and IoT security, along with network analytics and traffic management. It focuses on expanding its Security-as-a-Service (SECaaS) offerings through the Allot Secure product family, which delivers unified protection for consumers and SMBs across mobile, fixed, and 5G networks. Its Allot Smart solutions enable service providers to analyze and manage network data, optimize performance, reduce costs, and enhance user experience. It has a customer base in Europe, which generates maximum revenue, as well as in Asia and Oceania, the Americas, the Middle East, and Africa.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.